UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 4.

Renner, C; Zinzani, P L; Gressin, R; Klingbiel, D; Dietrich, P Y; Hitz, P; Bargetzi, M; Mingrone, W; Martinelli, G; Trojan, A; Bouabdallah, K; Lohri, A; Gyan, E; Biaggi, C; Cogliatti, S; Bertoni, F; Ghielmini, M; Brauchli, P; Ketterer, N (2012). A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica, 97(7):1085-1091.

Hitz, F; Martinelli, G; Zucca, E; von Moos, R; Mingrone, W; Simcock, M; Peterson, J; Cogliatti, S B; Bertoni, F; Zimmermann, D R; Ghielmini, M (2009). A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03. Hematological Oncology, 27(3):154-159.

Bernhard, J; Dietrich, D; Scheithauer, W; Gerber, D; Bodoky, G; Ruhstaller, T; Glimelius, B; Bajetta, E; Schüller, J; Saletti, P; Bauer, J; Figer, A; Pestalozzi, B C; Köhne, C H; Mingrone, W; Stemmer, S M; Tàmas, K; Kornek, G V; Koeberle, D; Herrmann, R (2008). Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial - SAKK 44/00-CECOG/PAN.1.3.001. Journal of Clinical Oncology, 26(22):3695-3701.

Borner, M; Koeberle, D; Von Moos, R; Saletti, P; Rauch, D; Hess, V; Trojan, A; Helbling, D; Pestalozzi, B; Caspar, Christian; Ruhstaller, T; Roth, A; Kappeler, A; Dietrich, D; Lanz, D; Mingrone, W (2008). Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the swiss group for clinical cancer research SAKK. Annals of Oncology, 19(7):1288 -1292 .

This list was generated on Fri Jul 21 01:27:18 2017 CEST.